2 weeks Ago By ABMN Staff
Alumis Inc. ( NASDAQ:ALMS – Get Free Report ) was down 4.8% during mid-day trading on Friday .
The stock traded as low as $11.23 and last traded at $11.40.
Approximately 37,219 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 188,853 shares. The stock had previously closed at $11.97.
Analysts Set New Price Targets A number of research firms have recently commented on ALMS. Leerink Partners initiated coverage on Alumis in a research note on Tuesday, July 23rd. They set an “outperform” rating and a $29.
00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research report on Monday, August 19th. Leerink Partnrs raised shares of Alumis to a “strong-buy” rating in a research note on Tuesday, July 23rd.
Guggenheim started coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $32.00 price target on the stock.
Finally, Morgan Stanley started coverage on shares of Alumis in a report on Tuesday, July 23rd. They set an “overweight” rating and a $36.00 price objective for the company.
Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Alumis currently has an average rating of “Buy” and an average price target of $27.50.
View Our Latest Stock Analysis on ALMS Alumis Stock Down 6.8 % Alumis ( NASDAQ:ALMS – Get Free Report ) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($23.
10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($21.53).
Analysts expect that Alumis Inc. will post -6.86 EPS for the current year.
Hedge Funds Weigh In On Alumis Institutional investors have recently bought and sold shares of the business. Maven Securities LTD purchased a new stake in Alumis during the second quarter worth $332,000. Millennium Management LLC purchased a new stake in shares of Alumis during the 2nd quarter worth $3,376,000.
Towerview LLC bought a new stake in Alumis during the second quarter valued at about $4,123,000. Ally Bridge Group NY LLC purchased a new position in Alumis in the second quarter valued at about $8,229,000. Finally, Yu Fan bought a new position in Alumis in the second quarter worth about $10,502,000.
Alumis Company Profile ( Get Free Report ) Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Recommended Stories Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter ..
